T 0702/22 (Apixaban I/BRISTOL-MYERS) of 21.12.2023
- European Case Law Identifier
- ECLI:EP:BA:2023:T070222.20231221
- Date of decision
- 21 December 2023
- Case number
- T 0702/22
- Petition for review of
- -
- Application number
- 17175864.2
- IPC class
- A61P 7/02A61K 9/20A61K 31/4545
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- APIXABAN FORMULATIONS
- Applicant name
- Bristol-Myers Squibb Holdings Ireland
Unlimited Company
Pfizer Inc. - Opponent name
- SANDOZ AG
Zentiva k.s.
Teva Pharmaceutical Industries Ltd
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Kutzenberger Wolff & Partner
von Seebach, Malte
Alfred E. Tiefenbacher (GmbH & Co. KG)
Wittkopp, Alexander
Generics (U.K.) Limited
STADA Arzneimittel AG - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112(1)European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Amendment to case
Novelty (yes)
Novelty - implicit disclosure (no)
Inventive step (no)
Inventive step - comparative example suitable starting point for assessing inventive step
Referral to the Enlarged Board of Appeal - (no) - Catchword
- -
- Citing cases
- T 1179/23
Order
For these reasons it is decided that:
1. The appeal is dismissed.
2. The request for referral to the Enlarged Board of Appeal is refused.